By Nick Paul Taylor
Pfizer is throwing its weight behind Valneva to support late-phase development of a Lyme disease vaccine candidate, agreeing to invest $95.6 million as part of a revised deal that triggered an 81% surge in its partner’s share price.
read more
By Conor Hale
Human Longevity, with its goal of helping people live past age 100, has inked a deal with a blank-check company to grab a spot on the New York Stock Exchange and collect $345 million.
read more
By Fraiser Kansteiner
After handing Novartis a win in January, a U.S. appeals court has changed course in a Gilenya patent infringement lawsuit. On Tuesday, the judges revived a Chinese drugmaker’s bid to challenge the blockbuster multiple sclerosis med with its copycat.
read more
By Heather Landi
A UnitedHealth Group unit plans to acquire EMIS Group in an all-cash deal that values the U.K. health technology company at about 1.24 billion pounds sterling, or $1.5 billion, the companies announced Friday.
read more
By Andrea Park
At a fork in the road, Aditya Khosla, Ph.D., is taking the path less traveled: one that will take him away from PathAI, the company he helped start half a decade ago.
read more
By Nick Paul Taylor
AstraZeneca’s $200 million bet on Ionis Pharmaceuticals’ rare disease drug has delivered an early win. A phase 3 trial of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy hit the mark at an interim analysis, teeing AstraZeneca to make an approval filing that will keep it hot on the heels of Alnylam.
read more
By Kevin Dunleavy
Now that the World Trade Organization has relaxed intellectual property restrictions on COVID-19 vaccines, the question is: Will any developing countries take advantage to produce their own shots?
read more
By Robert King
The Supreme Court struck down a lawsuit filed by DaVita that charged a health plan run by Marietta Memorial Hospital violated federal law by limiting dialysis coverage options.
read more
By Kevin Dunleavy
Visiting Washington, D.C., last week, Axcella CEO Bill Hinshaw is trying to enlist congressional allies to help with long COVID. He’s the first to admit that it’s not an easy sell.
read more
By Zoey Becker
Anticompetitive practices are even more unfair when there's only one competitor. The European Commission opened an investigation of Vifor Pharma's alleged disparagement of competitor Pharmacosmos, whose intravenous treatment might be Vifor's only competition.
read more
By Andrea Park
It’s been a rocky road, but Bioventus is finally back on track to acquire CartiHeal in the coming weeks.
read more
By Gabrielle Masson
9 Meters Biopharma’s celiac disease drug isn’t measuring up in a phase 3 trial. After an interim analysis found that the study needs an enrollment count that is too large to support continuation, the company is scouring data on sub-groups to see if the therapy may have a treatment effect.
read more
